Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

is symptoms using several different scales for endometriosis pain. The 6-month results from this study, together with data from the other Phase II studies, will be the basis for securing agreement on a registration plan with the Food and Drug Administration (FDA).

The Company is also currently conducting two additional randomized placebo-controlled Phase II clinical trials. The clinical endpoints for both of these trials are a reduction in pelvic pain associated with endometriosis, utilizing a scale proposed by the FDA. The first Phase II trial includes our selected commercial formulation tablet in two doses, (150 mg and 250 mg); this trial has completed randomization in 155 patients. The Company expects topline results from the first three months of treatment in the first quarter of 2009. The second trial is a four arm comparator trial of two doses of elagolix (150 mg and 250 mg), placebo or leuprolide depot. This trial is being conducted in Central and Eastern Europe. Topline data from this 3-month double-blind trial of approximately 180 patients should be available at the end of the first half of 2009.

Neurocrine is also investigating the potential of certain GnRH antagonists in treating other hormone-dependent diseases in Men's and Women's Health.

Corticotropin Releasing Factor (CRF1) Receptor Antagonists for Anxiety/Depression and IBS

The CRF collaboration between Neurocrine and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for mood disorders and irritable bowel syndrome (IBS). There are currently three distinct CRF compounds in clinical development that have arisen out of the GSK collaboration. The compound (876008) is in a Phase II "proof of concept" trial to evaluate its safety and efficacy in patients with IBS. Approximately 130 patients meeting established diagnostic criteria for IBS have been entered into this cross-over design trial.
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Mich. Every day, their baby stopped breathing, his ... his lungs. April and Bryan Gionfriddo watched helplessly, just ... "Quite a few doctors said he had a good ... Gionfriddo, about her now 20-month-old son, Kaiba. "At that ... would take it and run with it." , They ...
(Date:5/23/2013)... May 23, 2013 Patheon Inc ... services to the global pharmaceutical industry, will host a ... Approaches to Testing” on Tuesday, June 4, 2013 at ... manufacturers are required to comply with regulations for cleaning ... with limited scientific underpinning and little evaluation of risk. ...
(Date:5/23/2013)... May 23, 2013 VG Energy, an ... with DAK Renewable Research to conduct field trials ... VG Energy is a majority owned subsidiary of ... VG Energy,s exclusively licensed compound LipidMax selectively ... yield in plants, possessing a wide variety of ...
(Date:5/23/2013)... MUNDELEIN, Ill. , May 23, 2013 ... company providing value-added ingredients to a variety of industries, ... participated in a panel discussion at this year,s National ... May 20-21, 2013, on behalf of the Research Chefs ... Development for Restaurants: The Good, the Bad and the ...
Breaking Biology Technology:Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... War-era Chief Health Minister and scientist, General Vsevolod Ogarkov, had ... be used by 21st century American doctors and patients for ... flu season. Dr. Ogarkov,s team were the first researchers to ... system supplements. The probiotic-derived supplement Del-Immune V ...
... one of the world,s leading research and advisory firms ... the combined sales of seven new therapies for the ... in the United States, France, Germany, Italy, Spain, United ... indication, surveyed experts are particularly enthusiastic about agents in ...
... The food industry generates a lot of waste products, but ... to research published in the International Journal of Global ... of Calcutta and colleagues have demonstrated that the membrane that ... weight of the greenhouse gas carbon dioxide from the atmosphere. ...
Cached Biology Technology:Cold War Probiotic Discovery Now a Weapon in American Cold & Flu War 2Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019 2Scrambling for climate change solutions 2
(Date:5/24/2013)... In recent years, microRNAs (miRNAs) and other non-coding ... expression of specific proteins. In recent years they ... been used to establish tissue origin for cancers ... responses and screen for disease, but clinically tractable, ... samples are not currently available. In this issue ...
(Date:5/24/2013)... against Alzheimer,s disease, scientists have focused among other factors ... After all, it is the accumulation of A-beta that causes ... point for the formation of A-beta is APP. Alessia Soldano ... the function of APPL the fruit-fly version of APP ... Alessia Soldano (VIB/KU Leuven): "We have discovered that APPL ensures ...
(Date:5/23/2013)... Plant Science , Automated conserved ... and promoter evolution among grasses , Within the ... of DNA that undergo little change in position and ... for any proteins. Some of these evolutionarily stable sequences, ... the expression of other genes or the condensation of ...
Breaking Biology News(10 mins):A new strategy required in the search for Alzheimer's drugs? 2Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3
... Innovotech Inc. (TSX-V: IOT), a pioneer in the field ... of $900,000 from Agriculture and Agri-Food Canada to facilitate ... treatment and plant spray designed to protect crops against ... to increase crop yields and improve product quality while ...
... the expansion of protected area systems could ultimately protect ... a new paper in the scientific journal Nature ... Climate Adaptation Flagship and The University of Queensland said ... the performance of protected area systems by replacing a ...
... The bottled water, soda pop, or micro brew-beer that you ... contains a natural chemical imprint related to geographic location. When ... in your hair that could be used to track your ... to be the first concerted effort to describe the use ...
Cached Biology News:Conserving nature and dollars: Delivering cost-effective biodiversity protection 2Beverages leave 'geographic signatures' that can track people's movements 2
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
Biology Products: